Keyphrases
COVID-19
100%
Placebo Groups
100%
Placebo
100%
Randomized Double-blind
100%
Phase II Trial
100%
Remdesivir
75%
Sustained Recovery
75%
Hazard Ratio
50%
Modified Intention-to-treat
50%
Rate Ratio
50%
Recovery Rate
50%
Cumulative Incidence
25%
Improved Outcomes
25%
Consecutive Days
25%
Organ Failure
25%
Serious Adverse Events
25%
Neutralizing Monoclonal Antibody
25%
Safety Outcomes
25%
Neutralizing Antibodies
25%
Hospital Discharge
25%
Efficacy Analysis
25%
Mechanical Circulatory Support
25%
Renal Replacement Therapy
25%
Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO)
25%
Europe
25%
Safety Analysis
25%
Placebo-controlled Trial
25%
U.S. National Institutes of Health
25%
Pharmacist
25%
Invasive Mechanical Ventilation
25%
Singapore
25%
Uganda
25%
Co-primary
25%
Antibody Combinations
25%
Clinical Providers
25%
Antibody-negative
25%
Days at Home
25%
Vasopressor Therapy
25%
Operation Warp Speed
25%
Tixagevimab
25%
Medicine and Dentistry
COVID-19
100%
Placebo
100%
Remdesivir
33%
Hazard Ratio
22%
Intention-to-Treat Analysis
22%
Adverse Event
11%
Cumulative Incidence
11%
Monoclonal Antibody
11%
Renal Replacement Therapy
11%
Study Participant
11%
Infusion
11%
Assisted Circulation
11%
Artificial Respiration
11%
Extracorporeal Membrane Oxygenation
11%
Hypertensive Factor
11%
Neutralizing Antibody
11%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Remdesivir
33%
Adverse Event
11%
Monoclonal Antibody
11%
Replacement Therapy
11%
Hypertensive Factor
11%
Neutralizing Antibody
11%